Skip to content

Effect of paraspinal nerve block combined with percutaneous auricular vagal nerve stimulation on pain and mood improvement in patients with acute herpes zoster

Effect of paraspinal nerve block combined with percutaneous auricular vagal nerve stimulation on pain and mood improvement in patients with acute herpes zoster

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060651
Enrollment
Unknown
Registered
2022-06-06
Start date
2022-05-31
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute herpes zoster

Interventions

experimental group:Patients in the experimental group were treated with paraspinal nerve block combined with percutaneous auricular vagal nerve stimulation.Electrical stimulation of the left ear was p
control group:In the control group, the electrode of the instrument was placed at the corresponding position, but no stimulation was given.

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria of HZ; 2.Age 50-85 years old; 3.Course of HZ = 4; 5.Sign informed consent form

Exclusion criteria

Exclusion criteria: 1.TaVNS: installation of cardiac pacemaker or other electrical stimulation treatment; 2.Can not cooperate with treatment: such as dementia, Parkinson's syndrome, epilepsy 3.Craniofacial herpes 4.Irritation and puncture site skin infection or skin damage 5.The patients with severe abnormality of heart, lung, liver and kidney function or abnormal bleeding and coagulation time were not tolerant to the drugs needed for treatment 6.Rheumatic inflammatory diseases: rheumatoid, ankylosing spondylitis, etc. 7.The patients with poor blood glucose control: HbA1c > 9% 8.In the past week, take drugs that specifically affect autonomic nervous function, including sedatives or antidepressants 9.Long-term history of steroid use or malignant tumor 10.Those who are participating in or have participated in other clinical trials in the past 12 weeks

Design outcomes

Primary

MeasureTime frame
pain scores;

Secondary

MeasureTime frame
sleep quality;HAMA;

Countries

China

Contacts

Public ContactWen Shen
shenwen670201@163.com+86 18052268689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026